Digital Transformation

The confluence of data science and molecular biology fuels expectations among biopharma industry leaders for another year of breakthrough innovation in human therapeutics. More than 70 executives and experts reveal what they are most excited about on the technology front.

Digital maturity of clinical operations at several big pharma firms varies significantly with the gap between best-in-class and the industry average narrowest for site selection tools, recruitment capabilities, and automation, a study has indicated. Digital patient experience tools figure among the least mature capabilities.

The company is spending up to £562m to acquire artificial intelligence/machine learning provider InstaDeep, which it has partnered with since 2020, as competitor Moderna has made digital technology a cornerstone of its strategy. 

More foreign pharma firms, this time Sanofi and GSK, are reorganizing sales and marketing efforts accompanied by layoffs in India. Scrip talks to experts about what’s driving the right-sizing and the wider trend.

Scrip takes a look at the current landscape in the South Korean digital therapeutics sector, where some remaining gaps in regulation and reimbursement are seen but multiple products are now progressing through pivotal local clinical trials.

Industry experts at BioFuture 2022 highlighted the growing importance of digital technology in drug discovery and development, and also the limitations remaining.

During a panel at the 2022 BioFuture conference, panelists talked about how digital technology can provide data about drugs and devices on the market or in clinical trials.

To enable broader use of clinical data in its digital health care system, Japan has kickstarted digitization measures to link all patient records to an online individual ID system. While the government aims to allow real-world data and evidence for the pharmaceutical sector in the long run, Scrip explores the reality of current projects and measures in the country.

In this week's podcast edition of Five Must-Know Things: J&J and Roche’s first-half wins and challenges; Alexion’s Ultomiris plans; GSK’s AI and genomics investments; and a wide-ranging chat with the former secretary of the US department of Veterans Affairs.

The Oxford University spin-out has raised $37.5m in a series A thanks to its technology which pinpoints the link between genes and diseases and maps pathways for drug discovery.

The former Secretary of the US Department of Veterans Affairs, David Shulkin, discusses in an interview with Scrip the US Inflation Reduction Act, telehealth,  interoperability of healthcare data, and Mark Cuban’s pharma venture.

From AstraZeneca’s training program for its representatives to Pfizer’s campaign to drive vaccination in Brazil, the industry is taking a leaf out of Nike’s playbook in adopting the metaverse. Novartis’ executive director and AZ’s director of learning discussed applications and challenges at a recent event.